Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren versus irbesartan and combination therapy in type 2 diabetic nephropathy
2005-000362-39Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aliskiren and irbesartan in diabetic glomerulosclerosis, hypertension (HTN) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novartis. Primary endpoints: Primary pharmacodynamic renoprotection comparison and Additive renoprotection with combination therapy. Started Apr 2005; status: completed.
02
Drugs
aliskirenirbesartan
03
Conditions
diabetic glomerulosclerosishypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-000362-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000362-39.